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,Abstract: 
Protein kinases play a central role in signal transduction pathways. Many studies have 
reported that MAPK pathways are implicated in growth, differentiation, apoptosis and immunity. 
p38 MAPK is one of the major groups within the MAPK superfamily. Recent studies indicate that 
the p38 MAPK signalling pathway is one of the major intracellular signalling pathways regulating 
myogenesis. 
Identification of kinase substrates is a major goal of kinase biology. In order to identify 
p38 MAPK substrates, we have generated mutations in human p38a to create a structural 
distinction between the ATP binding site of p38 MAPK and that of other kinases in the cell in 
order to identify its substrates using modified nucleotide analogs. Identification of the relevant 
substrates will help to clarify the molecular mechanism underlying the role ofp38 MAPK. Here, it 
is shown that engineered kinases, are able to use synthesized ATP analogs, which are typically not 
recognized by natural kinases. In particular, this work demonstrates that Leu87Ala/Thr106Gly p38 
MAPK could be useful in a proteomic approach for identifying novel p38 MAPK substrates. 
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Chapter 1: Introduction 
The role of kinases in cellular processes: 
The eukaryotic protein kinases are one of the largest most functionally diverse 
gene families (1 ). The family of eukaryotic protein kinases consist~ of a total of 518 
human protein kinases, a total of 4 78 protein kinases have been identified through 
analysis of human sequence sources (2). Protein kinases mediate most of the signal 
transduction in eukaryotic cells. This is done by modifications of substrate activity. 
Protein kinases also control many other biological processes, among those; metabolism, 
transcription, cell cycle progression, cytoskeletal rearrangement apoptosis and 
differentiation. Mutations and dysregulations in protein kinases play a major role in 
human disease (2,3). The eukaryotic protein kinases are homologous proteins. They are 
related by conserved sequence of kinase domains, also known as catalytic domains. The 
catalytic domain of the protein kinase serves three major roles: 1- binding and orientation 
____ <!f_an ~deno_si_11:~_triphosp~-~~~ (~TJ>) or gu~osi11e triphosphate (GTP) molecule_ in a 
complex with divalent cation (Mg +2 or Mn +2), 2- binding and orientation of substrate, 3-
transfer of they-phosphate group from ATP or GTP to the serine, threonine or tyrosine 
residue of the protein substrate (4). Most of the protein kinases belong to a single 
superfamily containing a eukaryotic protein kinase catalytic domain ( 1 ). The protein 
kinase family has two main subdivisions: the protein-serine/threonine kinases and the 
protein-tyrosine kinases (4). These two families can be devided into the following major 
families: CMGC- includes the cyclin-dependent kinases, mitogen activated protein 
kinases, glycogen synthase 3 family, Cdk-like kinase famliy; STE- homolouges of yeast 
1 
Sterile?, Sterile 11, Sterile 20 kinases; CKl- Casein kinase 1; AGC- includes the cyclic-
nucloetide-dependent family (PKA and PKG), protein kinase C (PKC) family; CAMK-
Calcium/calmodium-dependent protein kinases; TK-Tyrosine kinase; and TKL-Tyrosine 
kinase-like. Members of the same kinase family have the same domain structure (2,4). 
Most protein kinases act in a network of kinases and other signalling effectors. 
They are characterized by autophosphorylation and phosphorylation by other kinases (3). 
Protein phosphorylation pathways regulate basic aspects of cell physiology, and are 
conserved throughout the eukaryotic evolution. Protein phosphorylation is a major 
regulatory mechanism. By adding the phosphate groups to substrate proteins, protein 
kinases direct the activity, localization and overall function of many proteins (4). The 
protein kinase family is stimulated by an extracellular signal, this stimulation results in 
intracellular signals that leads to activation of protein kinases, which in turn leads to 
phosphorylation of a specific substrate. Phosphorylation of the substrate alters the ability 
to interact with other molecules in the cell, what leads to diverse physiological responses 
. - . - . -·-- - ·-----·· - ·-. ·- - -· 
(3). Protein phosphorylation also plays a critical role in intracellular communication 
during development, homeostasis and in the functioning of the nervous and immune 
system (2). 
The regulation of eukaryotic protein kinases can occur on many levels, among 
those regulations; control of synthesis, posttranslational modification, binding of 
regulatory proteins, and the most common mechanism to regulate protein kinases activity 
is by phosphorylation key residues of the catalytic domain by other upstream protein 
kinase (3). 
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The biological impact of p38: 
p38 MAPK has many physiological roles and it is involved in the control of many 
cellular pathways. Importantly, p38 MAPK has been shown to play a role in myogenesis 
and development. p38 MAPK is known to have a role in regulating gene expression at the 
transcriptional level (5). This section will focus on the roles of p38 MAPK and emphasize 
the importance of identification of its targets. 
The role of p38 MAPK in myogenesis: 
Myogenesis, the process of muscle cell formation is essential for normal 
development, and is also implicated in pathological conditions. In mammals, myogenesis 
begins shortly after gastrulation and lasts until the end of post-natal growth (6). Protein 
kinases play a major role in myogenesis. Mitogen activated protein kinase (MAPK) 
signalling is necessary for the maintenance of skeletal mass. Inhibi1tion of these signalling 
cascades will cause muscle atrophy in vitro and in vivo (7). Skeletal myogenesis is a 
dynamic multistep process in which undifferentiated mononucleated myoblasts 
proliferate, withdraw from the cell cycle, and then differentiate and fuse to form the 
multinucleated mature muscle fibres, which are called myotubes ( 5). MAPK members 
regulate the formation of multinucleated myotubes, among those proteins is ERK 1 /2 
pathway, which is necessary for muscle growth (7). Differentiation of skeletal muscle is 
a crucial step in development. Protein kinase C (PKC) is expressed in fetal muscle cells. 
This kinase mediates growth and differentiation (8). The process of myogenesis is 
regulated by signalling pathways in response to extracellular cues. Among these is the 
3 
p3 8 MAPK pathway. The process of skeletal myogenesis is controlled by muscle specific 
basic helix-loop-helix (bHLH) proteins, which are known as the muscle regulatory factors 
(MRF's) (9). These factors bind to specific DNA elements.called,E-boxes on muscle 
related gene promoters and activate transcription. The MRF family consists of MyoD, 
Myf5, MRF4 and myogenin. Those proteins ensure proper muscle differentiation. All the 
MRF members bind to specific DNA elements that are present in the promoters of many 
muscle-specific genes (10,11). 
MyoD is considered to be a major transcription factor in muscle formation. MyoD 
triggers myoblast differentiation by activating the expression of my~genln. Myogenin is a 
muscle- specific transcription factor that induces myogenesis. Myogenin is necessary for 
the formation of myotubes (12).The other family of transcription factors that controls the 
expression of genes that contribute to initiation of the differentiation program and also 
maintance of the differentiated state is the Myocyte enhancer binding factor 2 (MEF2) 
(13). 
•• •• 
Progenitor 
cells 
MyfS 
MyoD Myogenin 
MEF2 
- '\. 
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Myotube 
Figure 1: The stages of muscle development- myogenesis.Myogenesis strats from progenitor mesodermal 
cells, which are the control of Myf5 and MyoD form myoblasts. Myoblasts fuse and form the mature 
myotube, which the muscle fiber. This is done under the control of Myogenin and MEF2 family 
transcription factors. 
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p38 MAPK affects the activity ofMRFs,which takes part in remodelling the 
chromatin at the muscle-regulatory specific regions. p3 8 MAPK plays a significant role in 
the signalling pathway of myogenesis and plays a role in several stages of the myogenic 
program (14). p38 MAP kinase activity increases during differentiation, and is also 
required for full myoblast differentiation and fusion (5). 
Recent studies have shown that p38 MAPK is probably one of the major 
intracellular regulators of the myogenesis pathway(l4). p38 MAPK activates myogenesis 
by phosphorylating the MEF2 proteins, to increase its transcriptional activity. It also 
increases the transcriptional activity ofMyoD (15). Through MyoD and MEF2,which 
bind directly to the myogenin promoter, p38 MAPK controls myogenin gene expression 
(13). Therfore, p38 MAPK is a key player in the regulation of muscle differentiation. 
p3 8 MAPK has four isoforms, but not all p3 8 isoforms lead to muscle specific 
gene expression. Interestingly, p38a is the isoform that has a main role in myogenesis (5). 
p38a not only promotes muscle differentiation and fusion, but is also a critical regulator 
of myoblast cell cycle exit. p38a also has the same effect on myoblast differentiation: 
mice lacking p38a failed to form myotubes (5). p38a is essential for embryonic 
development and deletion of the gene will result in embryonic death due to placental 
defects(16). Lack of other isoforms did not show any phenotypic changes(5). 
All of this illustrates that the p38a isoform has a central role in myogenesis. Thus, 
it is of great interest to study the regulation of this kinase, and its downstream substrates. 
5 
p38 MAPK and inflammation: 
There is a strong link between the p38 MAPK pathway and inflammation. There 
are several diseases that are thought to be regulated by p38 MAPK, among those are:· 
Alzheimer's disease, rheumatoid arthritis and inflammatory bowel disease (17). The 
activation of the p38 MAPK pathway plays a role in the production of pro-inflammatory 
cytokines: IL-lp, tumor necrosis factor a (TNF-a), and interleukin 6 (IL- 6)(18). Studies 
have shown, that TNFa. is a key regulator of myogenesis and muscle regeneration through 
it activation by p38 MAPK (19). IL-6 is a multifunctional cytokine that plays a major role 
in response to inflammation, and it leads to activation ofp38 MAPK. Based on recent 
studies, p3 8 MAPK has also been implicated in having a role in T-cell cytokine 
production. p38 MAPK is a key regulator of pro-inflammatory cytokine biosynthesis at 
the transcriptional and translational level (21). A regulatory rol1e for p38 MAPK in 
proliferation and differentiation of immune system cells has also been established (22). 
Since p38 MAPK has been implicated in inflammatory responses and tissue 
remodeling, and since inflammatory cytokines have been shown to play an important role 
in airway inflamation, p3 8 MAPK has been implicated in having a role in pulmonary 
disease (23).This indicates that p38 MAPK activity is critical for normal immune and 
inflammatory response, and makes the p38 MAPK signalling pathway a promising target 
for autoimmune and inflammatory disease therapy. 
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p38 MAPK in cell cycle, senescence, apoptosis and tumoroginesis: 
In eukaryotic cells, there are evolutionary conserved pathways that control the 
various checkpoints in the cell. In response to DNA damage, these checkpoints will delay 
progression to the next phase. This will give time for DNA repair. There are two main 
checkpoints in the cell: G 1/S which will ensure that DNA synthesis is accurately 
completed, and 02/M, which will ensure that the division of the cell has been accurately 
completed (also called mitosis). p38 MAPK is involved in both checkpoints (16). 
MAPK is required for spindle assembly checkpoint mechanism. This mechanism 
is conserved evolutionary and is required for accurate transition of the genetic material to 
the daughter cells. When p38 is activated it can arrest the cell cycle in the M phase, which 
will lead to disruption of spindle formation (34). 
Apoptosis and arrest of cell growth is an important mechanism that will prevent 
cells from becoming cancer cells. In response to DNA double strand breaks, p38 MAPK 
is activated, which leads to G2/M cell cycle checkpoint by phosphorylating p53 (35). p53 
can lead to apoptosis in case that there is damage to the DNA, and the cell will not 
continue to mitosis phase and will not replicate itself (16).The role of p38 MAPK in 
apoptosis is dependent on the cell type and the stimuli that are expressed by the cell (24 ). 
p38 MAPK can function upstream and downstream of caspases, which is a family of 
proteases that play an essential role in apoptosis and necrosis, in apoptosis (17,25). As 
well, the strength of the signal in the activation pathway is known to play a key role in the 
cellular response. There is evidence that strong p38 MAPK activation signal will lead to 
apoptosis, while lower levels of p38 MAPK activity will be associated with cell survival 
7 
(17). Activation of the p38 MAPK pathway is required for apoptosis induction in several 
different cells. p38 MAPK is known to phosphorylate and ~ctivate p53, which is a direct 
regulators of the apoptosis pathway (26). When p53 is activated in response to DNA 
damage and abnormal prolifarative signals, this leads to induction of apoptosis. This puts 
p38 in the picture of apoptosis regulation (27). 
p3 8 MAPK also seems to have a role in tumorigenesis and senescence. A 
common feature of tumor cells is loss of senescence (27). It has been shown that p38 
MAPK activity was responsible for senescence in response to telomere shortening, H202 
exposure and chronic RAS oncogene signal. All of those signals are environmental stress, 
which will lead to activation ofp38 MAPK. Activation ofp38 MAPK will lead to 
activation of transcription factors, such as p53, that can lead to cell death (27). 
p3 8 MAPK is activated in response to stimuli that cause cell cycle arrest, or cell 
death; this results is activation of its direct substrate MAP kinase-activated protein 2 
(MAPKAP-K2). This will eventually lead to 02 phase delay (28). 02 phase in the cell 
- -
cycle serves as a DNA damage checkpoint before the cell enters mitosis and divides into 
two identical cells. This checkpoint is important to ensure that DNA replication will be 
correct. p38 MAPK is involved in restraining uncontrolled.cell proliferation. This leads to 
the idea that p38 MAPK acts as a tumor suppressor (29,30). One of the most common 
examples of p3 8 MAPK and tumorogenesis is rhabdomyosarcoma, a common tumor 
among children, where p38 MAPK inhibiting proliferation (30). The key role of p38 
MAPK in tumoroginesis is to promote growth arrest and apoptosis. 
8 
p3 8 MAPK has been shown to promote cell death in vitro , but there are some cell 
lines, such as non-small lung tumors cells, where p38 MAPK has been shown to lead to 
survival and promote cancer cell growth. p38 MAPK was activated in human lung tumor 
samples compared to normal cells (17,31,32). The molecular mechanism that will 
determine whether p38 MAPK will be pro or anti-apoptotic has yet to be determined. It 
might be related to the cell type or the nature of p38 MAPK activating signal (33). 
p3 8 MAPK is also participating in the G 1 /S phase of the cell cycle in response to 
osmotic stress and cellular senescence. It was also shown that p3 8a and p3 8y are required 
for G2 cell cycle arrest that is induced by UV irradiation (17,36). The p38 MAPK 
pathway inhibits cell cycle progression, by inhibiting expression of cyclin D, and also by 
phosphorylating p53, which is a tumor suppressor. Defects in the p38 MAPK pathway 
can lead to cell cycle defects and increased tumorigenesis. Similarly, decreased p3 8 
MAPK activity, by inhibition ofMKK3 or MKK6, causes growth arrest defects in 
fibroblasts (3 7). 
p38 MAPK in cardiovascular dysfunction: 
Stress can activate cardiac hypertrophy, apoptosis and necrosis, which lead to 
ischemia of the heart. Stress will activate the stress-activated protein kinase pathway, 
among which is p38 MAPK. Ischemia in the heart will lead to activation of p38 MAPK. 
p38a is a dominant isoform that is found in the heart. It is yet unknown whether p38 
MAPK in heart failure will rescue cardiac damage or will lead to heart failure; it seems 
that it also depends on the system studied. Studies with human hearts, at the end stage 
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failing hearts, were inconsistent with the observations made in mice hearts (38). Ischemia 
induced inhibition of p38 MAPK activity protects against necrosis and apoptosis. In 
another study, it was shown that activation of p38 MAPK in cardiac myocytes leads to 
phosphorylation of other proteins, and provides protection and improves cardiac function 
after myocardial infarction. It seems that p38 MAPK can promote specific remodeling 
processes in heart failure (39).Another study has shown that p38u MAPK activity is 
required for neointima formation after arterial injury and also for vascular smooth muscle 
cell prolifiration ( 40). 
Understanding p3 8 MAPK targets could provide a better picture of how p3 8 
MAPK functions and contribute to drug development and treatment of heart failure. 
Molecular regulation of p38 MAPK signalling: 
MAPK families have a highly conserved signal transduction pathway,which 
combines different extracellular signals to intracellular responses ( 42). 
There are three main MAPK families that have been characterized to date: 
extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and p38 MAPK 
( 41 ). All three MAPK families have different roles in the cells, but they all have a similar 
canonical pathway; activation of MAP kinases kinases kinase (MAP3Ks) is required to 
phosphorylate and activate MAP kinases kinase (MAP2Ks). The MAP2Ks are activating 
MAPK by dual phosphorylation of threonine and tyrosine residues on the activation loop. 
All the three main MAPKs have a specific sequence in their activation loop that is 
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recognized by MAP2K of the pathway (33). This spesificity gives the ability to a specific 
MAP2K to activate a particular MAPK selectively (37). 
p38 MAPK is activated in response to cellular stress, such as UV irradiation, heat 
shock, high osmotic stress, protein synthesis inhibitors, proinflamatory cytokines and 
certain mitogens (19). It also, however, has a role in the immune response and plays an 
important role in cell survival and regulation of cell checkpoints ( 43). The activation of 
p38 MAPK is not only dependent on the stimulus, but also on the cell type (17). All the 
three MAPKs pathways have a cross talk between each other, and they can either activate 
or suppress each others activity. For example, ERK can activate JNK (44). On the other 
hand, stress activated JNK and p38 pathway suppress the survival-promoting activity of 
the ERK pathway (45,46). The MAPK pathways are regulated by several different 
signalling pathways, as well as by cross-talk within the MAPK family. The cross talk 
between the MAPK members contributes to decision of the cell whether to divide or 
terminally differentiate ( 4 7). 
- - -- - - - -
p3 8 MAPK has a role in regulating gene expression at the transcriptional level. 
Post-transcriptional regulation of inflammatory gene expression has also been linked with 
the p38 MAPK pathway. The p38 MAPK pathway is also involved in the induction of 
both cell cycle checkpoints Gl/S (synthesis of the DNA) and G2/M (division of the cell): 
its role has been better established in the G2/M checkpoint. Studies have shown that p38 
alpha and gamma are required for UV-induced G2 cell cycle arrest. p38 MAPK 
phosphorylates and activates p53, which leads to the induction of p53-dependent G2/M 
checkpoint, this will result in cell cycle arrest (48,49). The p38 MAPK pathway is an 
11 
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important regulator of protein turnover. There is evidence that indicate that p38 MAPK 
activity is critical for normal immune and inflammatory response (16). Furthermore, p38a 
plays a central role in myogenesis, whereby myoblasts fail to differentiate to 
multinucleated myotubes in mice lacking this kinase (5). 
As any many other protein kinases, the activation of p3 8 MAPK requires 
phosphorylation. This phosphorylation on the activation loop (Thr180 and Tyr182) leads 
to conformational changes and stabilizes it. It is suggested that Thr 180 is required for 
catalysis, while Tyrl 82 is required for substrate recognition. These conformational 
changes will facilitate substrate binding (50). p38 MAPK is activated by MAP2Ks, which 
is activated by MAP3Ks (figure 2). The diversity and the regulatory mechanism of 
MAP3Ks allow for diverse responses to many different stimuli of the cell, and to 
integrate p38 MAPK activation with other signalling pathways (43). MAP3Ks that have 
been reported to activate the p38 MAPK pathway are TGF-~- activating kinase l(TAKl), 
apoptosis signal-regulating kinase 1 (ASK-1) and mixed lineage kinase 3(MLK-3) (41). 
- -- . ~ - . -
Activation of p3 8 is very specific, and occurs through MKK6 and MKK3, which are the 
MAP2Ks. There are also studies that show that MKK4 also activates p38 MAPK, but it 
does not lead tO phosphorylation of all .p38 MAPK isoforms. Interestingly, MKK4 usually 
leads to phosphorylation of JNK (35). Activation of MAP2Ks also requires 
phosphorylation. Their phosphorylation occurs at two conserved sites: serine 151 and 
threonine155 (43). 
p38 MAPK is controlled by phosphorylation and dephosphorylation of the 
activation loop, at Thr180 and Tyr182 residues (35). Protein phosphatases inactivate p38 
12 
MAPK pathway. Among those phosphatases are type-2 family phosphatases (PP2C) and 
protein tyrosine phosphatases (PTP) that dephosphorylate tyrosine residues and lead to 
inactivation (51 ). Unlike other kinases, p38 MAPK has no nuclear localization signal, and 
it is distributed throughout the nucleus and cytoplasm. In response to activation, p38 
MAPK is translocated from the cytoplasm to the nucleus. This translocation does not 
require catalytic activity; it is induced by phosphorylation at Thr180 and Tyr182 (52). 
Phosphorylation of the p38 MAPK activation loop is critical for the nuclear translocation 
in response to DNA damage. This induces a conformational change and conformational 
reorganization, and stabilization of the activation loop, to facilitate substrate binding (23). 
The ability of kinases to phosphorylate their substrates is due to the presence of 
docking domains, which are the binding domains of the substrate. The sequence of the 
docking domain seems to determine the binding specificity of the kinase to a substrate 
(53). p38 MAPK phosphorylates its substrates usually on the Ser-Pro or Thr-Pro motifs. 
There is also some evidence that indicates that p3 8 MAPK can bind to various proteins 
without phosphorylating them. This may be due to structural changes of the targets, 
changes to their subcellular localization or competition with their binding to other 
proteins (43). Very importantly, p38 MAPK have a large numbetof cytosolic proteins 
and transcription factors that it can phosphorylate; among those are the Bcl-2 family, 
MEF2 family, p53, cyclin Dl, activating transcription factor 2(ATF-2) and many others. 
Thus it is evident that p38 MAPK plays a major role in protein regulation, and has a role 
in regulating gene expression at the transcription level. 
13 
Activation of the p38 MAPK pathway by cytokines will usually lead to cell 
differentiation, while activation of p38 MAPK pathway through environmental stress will 
lead to cell death. Those two outcomes discriminated by the strength of the signal (35). 
The strength of the signal, whether there is persistent stimulation of p3 8 MAPK, will 
determine whether p38 MAPK will lead to cell growth or cell arrest and death. It seems 
that enforced activation ofp38 MAPK will lead to growth arrest, while activation by 
inflammatory cytokines leads to temporary activation of p3'8 MAPK, this might be due to 
activation of parallel pathways, such as JNK. It is still remains to be defined what leads to 
the two different outcomes when p38 MAPK is activated (30,43). 
14 
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Figure 2: p38 MAPK pathway signalling.p38 MAPK is activated in response to stress signals outside the 
cell. This will lead to activation of MAP3K, which will phosphorylate and activate MAP2K, and it will in 
turn phosphorylate and activate p38 MAPK. Phosphorylation ofp38 will cause to its translocation from the 
cytoplasm to the nucleus, which will lead to phosphorylation of many different substrates, which will lead 
to different biological responses. 
p38 MAPK and its substrates: 
p38 MAPK was identified in 1994. Since then, a number of its substrates have 
been also identified. The identification of physiological substrates was done by several 
ways; use of specific pyridinyl imidazole inhibitors, such as SB203580 and SB202190 
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(54,55), mutagenesis of amino acids at phosphorylation sites of the substrate (52), and use 
of knockout mice that are dificient for each of the p38 MAPK isoforms individually 
(55).Identification of p38 MAPK substrates is of widespread interest due to its important 
role in the cell regulationbut, so far, its substrates are incompletely characterized. 
Among the substrates that were identified are: MAPKAP K2, 3 and 5. They are 
phosphorylated by p3 8 MAPK in response to inflammatory cytokines or environmental 
stresses that the cell is exposed to (23). p38 MAPK activation in response to cell cycle 
arrest or cell death will also lead to activation of MAPKAP K2 (28). MAPKAP K2 acts 
not only as a substrate, but also determines p38 MAPK cellular localization (23).p38-
regulated/activated protein kinase (PRAK) is phosphorylated when the cell is stress 
induced (56). MAP kinase-interacting kinase 1 and 2 (MNK.112) and Mitogen and stress 
activated kinase 1 (MSKl), both are activated in response to growth factors or 
environmental stress. Ribosomal S6 kinase-B (RSK-B), which phosphorylates 
transcription factor CREB (23). 
p38 MAPK also phosphorylates transcription factors, such as p53,activation 
transcription factor 2 and 6 (ATF-2/6) (23,57), MEF2A and MEF2C (58). As mentioned 
before, p53 is pro-apoptotic and has a role in cell cycle checkpoints (26). MEF2A and 
MEF2C have a role in many cellular functions and in neurons, skeletal and cardiac 
muscle tissues. MEF2 plays a role in the differentiation of these cell types, and in neurons 
it also has a role against neuronal apoptosis. MEF2 is phosphorylated by p38 MAPK on 
Thr312 and Thr319 residues, which leads to its increased transcriptional activation (59). 
ATF-2 is phosphorylated by p38 MAPK at Thr69 and Thr71 residues. Upon activation, 
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interacts with regulatory proteins, such as the retinoblastoma (Rb) tumor suppressor. 
ATF-2 can contribute to global transcription and DNA damage response, and it also has 
oncogenic activities and can act as a tumor suppressor (57). Another transcription factor 
substrate is C/EBP homologous protein (CHOP). p38 MAPK phosphorylate CHOP on 
Ser78 and Ser81 , this results in increased transcriptional activity of CHOP. CHOP 
accumulates under stress conditions (60). p38 MAPK also phosphorylates Elkl and SAP-
IA (61). p388 phosphorylates the cytosolic protein stathmin, which is involved in the 
regulation of microtubule dynamics ( 62). Tau, is a protein that is found in neurofibrillary 
lesions of Alzheimer's disease, is also phosphorylated by p38y and p388. Phosphorylation 
of Tau leads to its ability to promote microtubule assembly (63). 
As we can see, p38 MAPK has many different types of substrates that it can 
phosphorylate and activate. These substrates are activated by different stimuli and can 
have diverse effects within the cell. Knowing more about p3 8 MAPK substrates and 
understanding those that are already identified will provide a unified view of the p3 8 
MAPK signalling pathway. 
Structure of p38 MAPK: 
The p38 MAPK family plays a key role in the cell-cycle regulation, inflammation 
and apoptosis (enhanced p38 MAPK activity leads to apoptosis, hence it can be used in 
cancer treatment). It belongs to a larger group of mitogen activated protein kinase 
(MAPK). (64). 
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p38 MAPK is approximately 38kDa protein. It has four isoforms, which are 60% 
identical at the amino acid level. Based on their expression pattern, substrate specificity 
and sensitivity to pharmacological inhibitors, they can be divided to two groups: p38 
alpha and beta, and p38 gamma and delta (16). p38a is expressed in most cells, while 
other isoforms are more tissue specific.p38P is being expressed in brain cells, while p38y 
is expressed in skeletal muscle cells, and p388 in endocrine glands (23,65). In addition to 
differences in tissue specificity expression, p38y and 8 cannot phosphorylate all 
substrates, while p38a and p38P can phosphorylate all substrates (55). p38 MAPK is 
activated in response to ultraviolet radiation (UV), cellular stress, pro-inflammatory 
cytokines, TNFa and inteleukin-1 (Ile-1). p38 MAPK must be phosphorylated first in 
order to achieve maximum enzyme activity: p38 MAPK is phosphorylated by dual 
phosphorylation at the Thr180 and Tyr182 at the conserved motifThr-Gly-Tyr, by an 
upstream kinase, MAP2K. The motif is located on the surface near the active site of p38 
MAPK and exposed to solvents. This conserved motif of Thr-Gly-Tyr is called the 
activation loop, and it contains 12 amino acids (including Thr-Gly-Tyr). Phosphorylation 
of the activation loop leads to activation of p38 MAPK (66). The dual phosphorylation of 
p38 MAPK causes conformational changes of the folded protein, which enhances its 
access to substrate; together these factors increase the enzymatic activity of the substrate 
(23). There are specific MAP2Ks that were identified to phosphorylate p38 MAPK: 
MKK6 and MKK3 (66). Phosphorylation ofp38 MAPK by MKK3 and MKK6 results in 
its phosphorylation and activation ( 41 ). 
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The structure of unphosphorylated p3 8 MAPK plays an important role in the 
regulation of the cellular cascade. Interestingly, a portion of the activation loop of 
unphosphorylated p38 MAPK blocks the substrate binding area by occupying the peptide 
binding channel with amino acids 170-178. This ensures that p38 MAPK is not active 
before its activation (66). Regulation of p38 MAPK signal transduction is important for 
the proper function of the cell, since activation of this pathway may lead to cell cycle 
arrest ( 67). 
p38a and other MAP kinases have a docking groove, where activating kinases, 
inactivating phosphatases and substrates bind. This docking site, however, is not where 
the binding site for substrates, where they are being phophorylated by the kinase (66). 
Those docking domains form a binding site for the kinase to phosphorylate its substrate. 
Those interactions between MAPK and their substrates are necessary for signalling (33). 
The p38a. catalytic ATP site is formed in a region between the N-terminal and the C-
terminal domains of the protein. The ATP binding site is ldcated on amino acids 106-112 
(64). The ATP binding site is formed by the glycin-rich loop (67). The N-terminal domain 
creates a binding pocket for the adenine of the ATP ring, while the C-terminal domain 
contains the catalytic base, the binding sites and the phosphorylation loop (66). 
Additional DFG (Phe residue of Asp-Phe- Gly) motif is known as a conserved 
motif, is buried in the hydrophobic pocket between the two lobes of the kinase. This motif 
enhances activation of the gatekeeper residue (Figure 3) (68). 
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DFG site 
C-terminal domain 
N-terminal 
domain 
Figure 3: Computational 3D structure of p38 MAPK.The structure of p38 MAPK demonstrates the 
gatekeeper residue, DFG site and the ATP binding site, which is located between the C-terminal and the N-
terminal domains. PDB ID: 1 CMS. 
Identification of kinase substrates: 
Protein kinases play an important role in many cell signalling pathways. 
Identification of the direct substrates of each kinase is still a challenge, due to the fact that 
all kinases use ATP to phosphorylate their substrates. There are a few methods that are 
being used by researchers to identify substrates of protein kinases. One of the techniques 
is a use of inhibitors. Since the inhibitors bind to -the ATP binding site, it also prevents 
from the kinase to phosphorylate it substrates, hence this is not the preferred technique for 
I 
substrate identification.For this reason a new technique was developed by K. Shokat in 
1997(69). In tpis technique, specific kinases of interest are engineered to accept an ATP 
analog that has bulkier substituents synthesized on the N 6 position, which will not be 
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developed to identify direct substrates of many kinases. This approach was used in a 
recent study to identify new substrates of PK.A (71 ). 
A recent technique has been developed to identify substrates. In this technique 5 ' -
4-fluorosulphonyl-benzoyladenosine (FSBA) is used in a whole-cell lysate. FSBA is an 
ATP analog that inhibits the kinase by occupying the ATP binding site. This technique 
uses FSBA to inhibit all endogenous kinases in the lysate. Once they are inhibited, any 
unbound inhibitor is removed and the kinase of interest is added to the cell lysate. To 
visualize phosphorylation of the substrates of the kinase of interest, yP32-ATP is added, 
any labelling that occurs is due to the kinase. Further the substrates are identified by mass 
spectrometry analysis (72). 
Substrate identification using ATP binding pocket mutations: 
The hallmark of using Shokat' s technique is that products of phosphotransfer 
reactions with the modified kinase are specifically labelled. This method allows for 
identification of substrates of a specific kinase, and subsequently to determine their role 
in intracellular signal transduction. Importantly, this method is based on the observation 
that all protein kinases have a structurally similar ATP binding domain that comes into 
close contact with the N6 position of ATP (70). 
This method of engineering kinases has been used by other groups to identify new 
substrates of different kinases, including CDKl (73), Rous sarcoma virus (69), ERK2 
(74) and JNK (75). 
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Identification of the relevant substrates of a medically important kinase can help to clarify 
the molecular mechanism in diseases and foresee side effects of treatment with kinase 
inhibitors (76). 
Therefore, it is of great interest to identify kinase substrates; our current study will 
specifically focus on human p38a MAPK. p38a MAPK has a central role in myogenesis, 
also p38 MAPK signalling pathway a promising target for autoimmune and inflammatory 
disease therapy. This makes p38 MAPK an interesting target to identify its substrates. 
In order to properly engineer the mutant kinase, there are specific criteria that 
need to be met. Firstly, the kinase should be able to accept an ATP analog that cannot be 
used by the wild type kinase. Secondly, it should be able to use ATP analog with high 
catalytic efficiency and finally should have the same substrate specificity as the wild type 
kinase (77}. More specifically, the engineered kinase will accept the ATP analog by 
modification of the ATP binding pocket (73 ), and thus mutated kinase will prefer to use 
the ATP analog as the phosphor donor for substrate phosphorylation. 
Modification of the ATP binding pocket is achieved by mutating the amino acid at 
the gate keeper residue, which is the residue within the ATP binding site of a kinase that 
controls the accessibility of the substrate. The gatekeeper residue is conserved as a large 
hydrophobic pocket, and mutation of this residue to Alanine or Glycine creates a new 
pocket that can be uniquely accessed by an ATP analog (78). Since the size of the 
gatekeeper residue affects the accessibility of the hydrophobic pocket mutation at this 
residue creates additional space that will expend the ATP binding pocket and will allow 
an ATP analog to bind, while still allowing the mutated kinase to retain its natural 
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substrate specificity (79). Additional mutation to the conserved DF.G (Phe residue of Asp-
Phe- Gly) is known to enhance activation of the gatekeeper residue in p38 (76). 
Once the mutation is generated in the kinase, it is necessary to find a compatible 
ATP analog, which will be utilized by themodified protein. 
In order to trace substrates phosphorylated by the modified kinase radioactive 
tagging of ATP analog with gamma P32 is used ·to identify direct substrates of a kinase. 
The kinase will catalyze the transfer of the gamma phosphate from ATP into the 
substrate. This will allow specifically label substrate of a specific kinase, what will allow 
identifying direct substrates of the kinase of interest in a pool of other kinases (figure 3) 
(76). Radioactive labelling allows us to track the substrates, only those proteins that are 
direct substrates of that kinase will become radio labeled. 
Kinase 
substrate 
Phosphorylatedk Kinase 
substrate 
gatekeeper . 
Figure 4: The approach to engineer a kinase to accept ATP analog. Smaller amino acid is generated as 
a point mutation at the gatekeeper residue of the kinase, which allows the kinase to accept an ATP analog, 
that have additional chemical group synthesized on the N6 position. 
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Chapter 2: Statement of Purpose: 
Recent studies have shown that p3 8 MAPK plays an important role as a key 
regulator of pro-inflammatory cytokine biosynthesis, which makes p38 MAPK a 
promising target for autoimmune and inflammatory disease therapy. p3 8 MAPK also 
plays a central role in myogenesis and embryonic development. Also, based on recent 
studies, there is a possible indication that p3 8 MAPK can act as tumor suppressor. All of 
these roles make it of great interest to study the regulation of p38 MAPK and its 
downstream substrates. There are some substrates that are already known, but many still 
remain unknown. Identification of the full inventory of direct substrates of kinases is a 
key factor in determining their roles in intracellular signal transduction. 
The long term goal of these studies is to identify novel substrates of human p3 8a. 
Identification of the relevant substrates of medically important kinases can help to clarify 
molecular mechanisms in disease and foresee side effects of treatments with kinase 
inhibitors. 
First, we wanted to generate mutations of p38 MAPK without losing its biological 
function. For this purpose we have generated mutations at the gatekeeper residue. The 
. purpose of generating mutations at the gatekeeper is to use them as tools for the 
identification of physiological substrates. This will distinguish the substrate preference of 
p38 MAPK from the rest of the cellular kinases in terms if ATP usage. The mutation was 
generated at the gate keeper residue, which controls the accessibility of the kinase to the 
substrate. The mutation was a smaller amino acid, which will create an additional pocket 
were an ATP analog can bind that cannot be accepted by wild type kinase. 
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The next step was to engineer our kinase ATP binding pocket, so that p3 8 MAPK will be 
able to accept and bind ATP analogs. Based on the 3D structure ofp38 MAPK we made 
an additional mutation that will modify the ATP binding pocket. Once mutations were 
generated, we wanted to test whether synthesized ATP can be accepted by these 
mutations. For this purpose, we have tested different ATP analogs (that were purchased 
from Bio log Life Science). The ATP analogs used were: N6-Bn-ATP, N6-
(2Methy1Butyl)-ATP and N6-Cyclopentyl-ATP. Our mutations, which are genetically 
engineered, should be able to use the more bulky synthesized ATP analog, which is 
typically not recognized by natural endogenous kinases. All protein kinases use ATP as a 
cofactor to phosphorylate their targets, that is why the identification cannot be done 
easily, and that is where the ATP analog plays a role. Lastly, our purpose was to use 
radiolabelled yP32 ATP in order to transfer a radioactive label to the substrate when the 
kinase uses the y P32 ATP in the catalytic reaction for identification of p3 8 MAPK 
substrates. By marking the substrates of engineered kinase with gamma-phosphate group 
of ATP analog, it can be specifically labelled in a complex mixture of other wild type 
kinases. The radioactive labelling allows it to track the substrates. Only the proteins that 
are direct substrates of p3 8 MAPK will become radio labeled. 
Therefore, the criteria that need to be met for engineered kinase are: 1) the 
mutated kinase should be expressed in the cell content, 2) the engineered kinase should 
accept ATP analogs, 3) the kinase should be able to phosphorylate a .known substrate, 4) 
the wild type p3 8 MAPK does not accept ATP analog. 
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Based on this initial approach, one can continue with identification of new substrates. A 
recent approach is to couple the transfer of the phosphate grnup to the identification of the 
substrate using mass spectrometry. 
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Chapter 3: Materials and Methods: 
Antibodies and plasmids: 
The following antibodies were used: a-Actin (cat.# SC-1616) and a-dsRED (cat.# 
G2307) were purchased from Santa Cruz biotechnology. Anti HA- 125CA5 supernatant 
was obtained from Developmental Studies Hybridoma bank. p38 (cat.# 9212), pp38 
(cat.# 9211) and pATF-2 (cat.# 9224) were purchased from Cell Signaling Technology. 
ATF-2 Fusion Protein was purchased from Cell Signaling Technology. Anti HA affinity 
matrix was purchased from Roche (cat.# 11815016001) 
PMT2 and HA-p38 we got from David Cox. MKK.6 
Cell culture: 
The COS7 cell line, which is derived from the African Green Monkey kidney were 
cultured in growth media (GM) which contains high-glucose Dulbecco's modified 
Eagle's medium (DMEM), 10% FBS (HyClone), 1 % penicillin-streptomycin and 1% L-
Glutamine (Gibco) at 37 °C and 5% C02. Cells were passaged at 60-70% confluency. 
(For details see appendix) 
Transient Transfectio~: 
Cells were seeded 24 hours before transfection. Transient transfection of cells was 
performed based on the calcium- phosphate precipitation method. Cells were allowed to 
recover in GM 16-18 hours after transfection. dsRED signal was confirmed 24 hours later 
and cells were harvested with lX cell lysis buffer. (For details see appendix) 
27 
Western Blot analysis: 
Total cell lysate were harvested with lX cell lysis buffer (see appendix) and supplements 
(lmM phenylmethylsulfonyl (PMSF) and lmM Na3 V04)· 
Equal volumes of protein for each sample (15µ1) were resolved by SDS-PAGE on 10% 
gels. Proteins were transferred electrophoretically to Immobilin-FL membranes 
(Millipore). Primary antibodies were diluted in appropriate buffer in the following ratios: 
Actin (1:2000), dsRED (1:2000), HA (1:20), p38 (1:3000), pp38 (1:3000) and p ATF2 
(1: 1500), and blots were incubated overnight in 4 °C. Blots were incubated in secondary 
antibodies at room temperature. ECL (GE) was added, and blots were exposed to film. 
(For more details refer to appendix). 
Immunoprecipitation and in vitro kinase assay: 
Total cell lysate was prepared in lX cell lysis buffer. Anti-HA beads were added to the 
total cell lysate and incubated overnight at 4°C. The pellets were washed 2 times with lX 
cell lysis buffer and twice with lX kinase buffer (based on Kinase Assay Kit from Cell 
Signaling Technology). The following was added to the pel1et: 250µM ATP or ATP 
analog, 2µg/ul ATF2 fusion protein (purchased from Cell Signaling Technologies) and 
lX kinase buffer for a total volume of 40µ1. The reaction was incubated for 30min at 
30°C. The reaction was stopped by adding 4X Lummeli sample buffer. Samples were 
boiled for 5 minutes at 95°C. Samples were run on 10% SDS-PAGE and western blot 
analysis was done to detect the proteins of interest. 
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6XHN NDPK protein purification and ATP analog labeUng: 
BL21 6xHN NDPK was purified on a column with Ni-Nta (nickel-nitriloacetic acid 
column) beads. Samples with the eluted fraction were resolved on a 15% SDS-PAGE gel 
and coomasie stained to assess protein levels and purity. The fractions with the highest 
NDPK levels were dialysed against three changes ofHKG buffer (see appendix). This 
was used for ATP labelling. 
165µg of purified 6xHN NDPK was added to a column with Ni-Nta beads. The column 
was washed with lX PBS. lmci of yP32 was added to the column. ADP analog was 
added to the column. yP32 ATP analog was eluted from the column. The eluate was used 
for radioactive in vitro kinase assays. The procedure for "hot" in vitro kinase assay was 
the same as the "cold" (for details see appendix). 
Mutagenesis: 
The mutations were constructed by polymerase chain reaction (PCR) with two sets of 
primers cloned into p38 MAPK. The various site mutations of p38 were generated using 
Quickchange II Site directed mutagenesis kit (Strata gene). Mutations were sequence 
verified (For details see appendix). 
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Chapter 4: Results: 
Generated mutations of p38 MAPK: 
We have generated mutations of wild type (WT) human p3i8a MAPK by site directed 
mutagenesis. Firstly, mutation at the gatekeeper residue (Thr106) was generated. 
Threonine was exchanged to a smaller amino acid Glycine or Alanine. Additional 
mutation was done at the conserved pFG motif, L167, w~ch is a conserved motif in p38 
MAPK that enhances the activity of the gatekeeper residue. Leucine was exchanged to · 
Alanine. The clones were screened for correct mutation by sequencing at the core facility. 
The following mutations were introduced into the DNA sequence: 1) T106G, 2) T106A, 
3) Tl06G + L167A, 4) T106A + L167A. 
Tl06G: 
GAGGAATTCAATGATGTGTATCTGGTGACCCATCTCATGGGGGCAGAT 
GAGGAATTCAATGATGTGTATCTGGTGGGCCATCTCATGGGGGCAGAT 
T106A: 
GAGGAATTCAATGATGTGTATCTGGTGACCCATCTCATGGGGGCA 
GAGGAATTCAATGATGTGTATCTGGTGGCCCATCTC~TGGGGGCA 
+L167A: 
GCTGTGAATGAAGACTGTGAGCTGAAGATT-CTGGATTTTGGACTGGCT 
GCTGTGAATGAAGACTGTGAGCTGAAGATTGC-GGATTTTGGACTGGCT 
Over-expression of MKK6 activates WT p38 and p38 mutations: 
Once mutations in p3 8 MAPK were generat~d, we wanted to confirm that p3 8 MAPK 
had not lost its catalytic activity, and the mutant forms of p38 MAPK are still able to be 
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activated by MKK.6. This was tested by exogenously expressing COS7 cells with WTp38 
and p3 8 mutations. PMT2, which is the vector p3 8 is cloned in, was used as a control. 
The results demonstrated in figure 4, indicate that the mutations that were generated did 
not affect the ability of p38 being activated by MKK6.The r:esults show that the generated 
mutations are phosphorylated at the same level as the WTp38, based on the pp38 
immunoblot. MKK.6 is a physiological upstream activator of p38 MAPK. Cells were co-
transfected with WTp38 or p38 mutations with the addition ofMKK.6. This was to test 
whether the generated mutations have changed the activity of p38 MAPK, or they are still 
phosphorylated by the biological activator of p38 MAPK. This was a preliminary 
screening to confirm that we can use our mutations for further experiments. 
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Figure 5:0ver-expression of MKK6 can activate p38 mutations. Western blot analysis in COS7 cells to 
over-expression of WTp38 and the 4 generated mutations of p38. PMT2 w~s used as an empty vector 
control, HA was used as a control to detect exogenously expressed p38, <ls.RED was used as transfection 
efficiency control, and Actin was used as a loading control. Phospho p38 was used to detect phosphorylated 
p38 after co-transfection with MKK6. 
The p38 mutations are as follows: Mut 1-T106G, Mut2- T106A, Mut3-T106G +Ll67A, Mut 4- T106A+ 
Ll67A. 
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Western blot analysis of in vitro kinase assay with N6-Bn-ATP shows that generated 
p38 mutations can accept an ATP analog and phosphorylate a known substrate 
(ATF2): 
Using the p38 MAPK mutations, an in vitro kinase assay was done with an ATP analog, 
N6-Bn-ATP, to confirm whether mutations ofp38 MAPK can use the ATP analog to 
phosphorylate a known substrate ofp38, ATF-2. To isolate exogenously expressed 
WTp38 and p38 mutations, p38 MAPK was immunoprecipitated with HA beads in order 
to pull down only exogenous p38 MAPK which is tagged with HA.COS7 cell line was 
used. WTp38 and p38 mutations were co- transfected with MKK6. The analog that was 
used is N6-Bn-ATP.This analysis helped us determine whether ATP analog can be used 
as a phosphate source by mutations ofp38 MAPK. 
The results demonstrated in figure 5 have shown that mutation to the gatekeeper residue 
(Thr106 to Gly) was able to phosphorylate ATF-2 more efficiently than Thr106 to Ala. 
Enhancement of that mutation with L 167 A was also able to phosphorylate the substrate, 
but it was not by far more efficient phosphorylation than mutation just to the gatekeeper 
residue, which was a surprise. Surprisingly WTp38 can also accept ATP analog and 
phosphorylate ATF-2. 
It seems that exchange to amino acid Glycine is better than to Alanine. Exchange to 
Glycine seems to phosphorylate ATF-2 more efficiently, which might be an indication to 
the fact that this mutation is able to accept ATP analog better. 
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18: pp38 
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Figure 6: In vitro kinase assay with mutations of p38 and ATP analog shows that generated mutations 
can phosphorylate known substrate ATF-2. Western blot analysis in [COS7 cells of an in vitro kinase 
assay with N6-Bn-ATP. The kinaseassay was done with ATF2. All the donditions were activated by co-
transfection with MKK6. 
PMT2 ':Vas used as a control, HA was used as a control to detect exogenously expressed p38. ATF-2was 
used to detect total ATF2 levels, while pATF-2 was to show phosphorylation by activated p38. pp38panel 
was to show that MKK6 successfully activated p38, and p38 was to show total p38 levels in thecell lysate. 
The p38 mutations are as follows: Mut 1- T106G, Mut2- T106A, Mut3-T106G +L167A, Mut 4-Tl06A+ 
L167A. 
Additional ATP analogs were tested in in vitro kinase assay with mutations of p38 
MAPK: 
Once we have generated mutation in p3 8 MAPK, it is necessary to find a compatible ATP 
analog, which will be utilized by the modified protein. Previous studies that were done on 
identification of new substrates, have tried few analogs with this labelling technique ( 69, 
74), to determine which analog will chemically match best, this will result in better 
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catalytic efficiency and better substrate phosphorylation.Different analogs were tried to 
test which analog will be the most compatible with p38 mutations (Fig 7). For this 
purpose we have used two additional analogs:N6- (2Methy1Butyl)-ATP and N6-
Cyclopentyl-ATP from Biolog Life Science company. All three analogs were tested in 
"cold" in vitro kinase assay with ATF-2. 
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Figure 7: Structural comparison of ATP and ATP analogs. A. Chemical structure of ATP. B. Chemical 
structure ofN6-Bn-ATP. C. Chemical structure ofN6(2-methyl butyl)ATP. D. N6(cyclopentyl)ATP. The 
benzyl group that is found at the N6 position of the adenine ring was synthesized to a bigger chemical 
group. Structure was adopted from Biolog Life Sciences. 
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Figure 8: Additional ATP analogs in in vitro kinase assay do not phosphorylate ATF-2 with the 
generated mutations. 
Western blot analysis of in vitro kinase assay ofWTp38 and mutation ofp38 co-transfected with MKK.6 in 
COS7 cells. PMT2 was used as control. The blots were probed with pATF2 to detect whether activated p38 
mutations by MKK.6 can phosphorylate known substrate in an assay with\ ATP analogs. The assay was done 
with different analogs. Blots were also probed with p38, to detect levels cif total p38 in the lysate after 
immunopercipitation. 
The p38 mutations are as follows: Mutl- Tl06G, Mut2- Tl06A, Mut 3- Tl06G +Ll67A, Mut 4-
Tl06A+Ll67A. 
These results demonstrate that the generated mutations of p3 8 MAPK are not accepting 
ATP analogs very efficiently.The reason for that can be that the amino acid Threonine is 
not a very big amino acid, and exchange of this amino acid to Glycine or Alanine does 
not open up the binding pocket of the substrates as much, hence the ATP analog does not 
bind in this pocket as efficiently and cannot be used to phosphorylate substrates of p38 
MAPK. In other studies that used this technique, usually the gatekeeper residue is a 
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bigger amino acid, like Methionine, and exchange of this type of amino acid to a smaller 
one will make a difference in the size of the ATP binding pocket. 
Analysis of the· three dimensional structure of p38 demonstrated that there is 
additional mutation that can be done in order to open ATP binding pocket further (Fig 
9A~ 9B, V. Saridakis). · 
A 
B 
Figure 9: Hypothetical computational analysis of p38 demonstrates that additional mutation to L87 
residue will increase the ATP binding pocket size: Computational structure ofp38 was tested. Based on 
the structure Tl06 and Ll67 that were already mutated are residues that_n~ed to be mutated to a smaller 
amino acid to open the ATP binding site. Though, the hypothetical computational analysis shows that L87 
residue is possible to be on the way to increase the ATP binding site (A). (B) Hypothetical computational 
analysis that shows how the ATP binding site will look like if all those three residues mutated to Alanine. 
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Additional mutation of p38 MAPK to L87 residue was g:enerated: 
Based on the computational analysis with the help of Dr. Saridakis, we have generated 
another mutation at the L87 residue; the amino acid was exchanged to Alanine. 
An additional 4 mutations were introduced into the DNA sequence. Table 1 demonstrates 
all mutations that were generated in p3 8 MAPK. 
Table 1: All the mutations that were introduced into the p38 MAPK DNA sequence 
Mut 1 T106G 
Mut2 T106A 
Mut3 T106G+L167 A 
Mut4 T106A+L167 A 
MutS L87A+T106G 
Mut6 L87A+T106A 
Mut7 L87A+T106G+L167A 
Mut8 L87 A+ T106A+L167 A 
Mut9 L87A 
The clones were screened for correct mutation by sequencing at the core facility. 
L87A+T106G: 
GTCTGTTGGACGTTTTTACACC 
GTCTGGCGGACGTTTTTACACC 
TATCTGGTGACCCATCTCATG 
TATCTGGTGGGCCATCTCATG 
L87A+T106A: 
GTCTGTTGGACGTTTTTACACCTT 
GTCTGGCGGACGTTTTTACACCTT 
TATCTGGTGACCCATCTCATGGG 
TATCTGGTGGCCCATCTCATGGG 
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L87A+T106G+L167A: 
TGGTCTGTTGGACGTT 
TGGTCTGGCGGACGTT 
ATGGTCTGGCGGACGT 
ATCTGGTGGGCCATCT 
AGCTGAAGATTCTGGATT 
AGCTGAAGATTGCGGATT 
L87A+T106A+L167A: 
GTGATTGGTCTGTTGGACGTTTT 
GTGATTGGTCTGGCGGACGTTTT 
ATCTGGTGACCCATCTCAT 
ATCTGGTGGCCCATCTCAT 
GAAGATT-CTGGATTTTGGACTGGCTC 
GAAGATTGC-GGATTTTGGACTGGCTC 
Western blot analysis of in vitro kinase assay with additional generated mutations of 
p38 and ATP analogs and ATF-2 as a substrate: 
A "cold" in vitro kinase assay was done with the additional mutations of p38 MAPK and 
all the three analogs, in order to confirm whether the new mutation has changed the 
chemical structure of the ATP binding pocket, and whether this will allow an ATP analog 
to bincl better and phosphorylate known substrate of p38 MAPK. All the three analogs 
were used to determine which analog can bind to the generated ATP binding pocket. 
As demonstrated in figure 10, it is observed .that the addition of the new mutation L87 A 
has changed the chemical structure of the ATP binding pocket and together with the 
gatekeeper residue mutation to T106G can very efficiently use an ATP analog to 
phosphorylate known substrate of p38 MAPK. Based on the results, we can see that N6-
38 
2MeBu-ATP is binding better to the ATP binding pocket. Even though we can see that 
other ·analogs are also phosphorylating ATF-2 (they are also accepted at the ATP binding 
pocket) N6-cPe-ATP and N6-Bn-ATP can also be accepted by WTp38, and N6-2MeBu-
A TP is not. This makes it a more promising analog for the identification purpose. 
Surprisingly, all the three mutations did not seem to have an ability to phosphorylate 
ATF-2, despite the fact that from the computational analysis it seemed that the 
combination with the three mutations would open the ATP binding pocket to its 
maximum for ATP analog to 'be accepted. The in vitro kinase assay shows that the 
· interacti~n between the ATP analog and the ATP binding site is not only based on size 
but also structural changes that are occurring with the protein. 
Regular ATP was used as a control to see whether an ATP analog can bind almost as 
efficiently to mutated p38 MAPK as regular ATP., which based or the results in figure 9 it 
was confirmed. 
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Figure 10: In vitro kinase assay with new p38 mutations and ATP analogs have demonstrated that 
N6-2MeBu-ATP analog is being utilized better than the other analogs by the new mutations and can 
phosphorylate know substrate of p38 ATF-2. Western blot analysis of in vitro kinase assay of WTp38 
and mutations ofp38 co-transfected with MKK6 in COS7 cells. PMT2 was used as control. The blots were 
probed with pATF2 to detect whether activated p38 mutations by MKK6 can phosphorylate known 
substrate in an assay with ATP analogs. Different analogs were tested to confirm which one uses the analog 
best. Blots were also probed with p38, to detect levels of total p38 in the lysate after immunopercipitation, 
and phsopho p38 used to detect leveis of activated p38 by MKK.6. 
The p38 mutations are as follows: Mut5- L87A+Tl06G, Mut6- L87A +Tl06A, Mut 7-
L87A+Tl06G+Ll67A, Mut8- L87A+Tl06A+L167A. 
Western blot analysis of in vitro kinase assay of L87 A mutation by itself with ATP 
analogs: 
Based on the structural analysis of p38 and the additional mutation to L87 residue, we 
wanted to confirm whether L87 A by itself can phosphorylate known substrate of p38-
ATF-2. An in vitro kinase assay with the L87 mutation, ATP analogs and ATF-2 as a 
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substrate was done. For comparison L87 mutation with the.gatekeeper residue and L87 
mutation with gatekeeper and conserved motif was also analysed on the western blot. 
As demonstrated in figure 11, the results showed that L87 A by itself can bind N6-Bn-
ATP and N6-cPe-ATP analogs and phosphorylate ATF-2, \hut N6-2MeBu-ATP does not 
bind to L87 A and does not phosphorylate the substrate. This is an interesting result, 
which indicates that L87 A does have an effect in binding ATP anafogs, as it shows that 
the addition of this mutation has made structural changes that enabled ATP analogs to 
bind to the ATP binding site of mutated p38 and phosphorylate ATF-2. It is interesting 
that the additional mutation of L87 A to the gatekeeper residue Tl 060 leads to better 
binding with N6-2MeBu-ATP analog, but L87 A by itself cannot bind. This is not the case 
with the other two analogs. 
Regardless, those results show that L87 A does contribute to the chemical changes at the 
ATP binding site and lead to better binding of ATP analogs. 
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Figure 11: In vitro kinase assay with new p38 mutations and L87 mutation IJy itself and ATP analogs 
demonstrate that L87 mutation modifies analog binding to the ATP:binding site. Western blot analysis 
of in vitro kinase assay ofp38wt and mutations ofp38 co-transfected wiith MKK.6 in COS7 cells. PMT2 
was used as control. The blots were probed with pATF2 to detect wheth~r activated p38 mutations by 
MKK.6 can phosphorylate known substrate in an assay with ATP analogs. Different analogs were tested. 
Blots ':Vere also probed with p38, to detect levels of total p38 in.the lysate after immunopercipitation, and 
phsopho p38 used to detect levels of activated p38 by MKK.6. 
The p38 mutations are as follows: Mut5- L87A+Tl06G, Mut6- L87A +Tl06A, Mut 7-
L87A+Tl06G+L167A, Mut8- L87A+Tl06A+Ll67A, Mut9- L87A. 
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Evolutionary sequence alignment of p38 MAPK: 
Based on our results, we have done an evolutionary sequence alignment of p38 MAPK. 
We wanted to confim1 whether L87 residue is conserved among the species. This is an 
indication that the residue is important if it is conserved through evolution. This 
alignment shows that p3 8 MAPK is conserved about 90% among the species, starting 
from drosophila to human. We can observe that L87 is conserved residue among the 
species. As well, the gatekeeper residue (Tl-06) and L167 are conserved residues 
evolutionary. The TGY motif, which is the activation loop, is also conserved. This is an 
indication that all of those residues have an important role in p3 8 MAPK, and they 
haveremained conserved through evolution. 
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Figure 12: Evolutionary sequence alignment of p38. Sequences wer~ aligned using Mu Ital in program. 
The gatekeeper residue at Tl 06 and the conserved motif at L167 are conserved among the species. The 
TGY motif is also conserved among the species, this is p38 is phosphorylated by MKK6/3. L87 is also 
conserved among the species. 
Sequence alignment of p38 MAPK and other kinases: 
Once we have done the evolutionary sequence alignment, we have done also an alignment 
of other protein kinases, this is to confirm whether L87 residue is conserved among other 
kinases as well. The alignment results showed that this residue is not conserved among 
other kinases. This residue is only conserved between JNK and p3 8 MAPK, which makes 
sense due to the fact that those two MAPKs are in the same sub-group. 
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Figure 13: Sequence alignment of p38 MAPK and other kinases. Sequences were aligned using 
Multalin program. The alignment was done to confirm whether L87 residue is conserved among other 
kinases as well. The alignment shows that this residue is conserved only among JNK and p38. 
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Chapter 5: Discussion: 
Protein kinases play a central role in signal transduction pathways. There are 
many studies that reported that MAPK pathways are implic:ated in many pathological 
conditions, including cancer. 
Recent studies indicate that p3 8a MAPK plays a role in regulation of 
inflammation pathways, which indicates that p38 MAPK activity is critical for normal 
immune and inflammatory responses. p38 MAPK also plays a role in cell cycle regulation 
and apoptosis, and can act as tumor suppressor. Furthermore, recent studies indicate that 
it also has a role in cardiovascular dysfunction. The most studied role of p3 8a MAPK is 
its central role in myogenesis and embryonic development. ]t seems that the p38 MAPK 
pathway and all the roles it plays in the cell can be used as potential targets for 
therapeutic intervention. Better understanding of p38 MAPK signalling cascades can help 
uncover important targets for drug design(76). 
In this study, we have generated mutations of human p38a and engineered its ATP 
binding pocket to accept and bind synthesized ATP analogs, which will enable us to 
identify substrates. ATP analogs are synthesized and have an additional group on the N6 
position, what makes them bulkier. ATP analogs cannot be accepted by wild type p38 
MAPK, and can only be accepted by the engineered kinase. Due to those structural 
changes, the substrates that will be specific to only that kinase can accept ATP analogs. 
Firstly, we generated a mutation at the gatekeeper residue (Thr106) ofp38 MAPK. 
Mutation of the Thr106 residue in p38 MAPK to an alanine or glycine should yield the 
space required to accommodate an ATP analog. Our results have shown that this mutation 
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did not affect p38 MAPK biological application and can still be phosphorylated and 
activated by its upstream kinase MKK6 (fig. 5). p38 MAPK is activated only after 
phosphorylation by MKK3 or MKK6. In our study, we have used MKK6 for 
phosphorylation and activation of p38 MAPK. Figure 4 show that we have total levels of 
p38 MAPK in the lysates. Co-transfection of wild type p38 or mutations of p38 with 
MKK6 has shown phosphorylated p38. With no MKK6 there is no phosphorylation of 
p38, when MKK6 co-transfected with p38 there is phosphorylation of p38 MAPK. This 
was an indication that the mutation we have generated did not affect p38 MAPK 
biological activity, and it can still be activated by MKK6. The next step was to engineer 
the kinase ATP binding pocket. We have generated additional mutations (additional to 
Thr106), at the conserved DFGmotif (L167) that is supposed to enhance gatekeeper 
residue binding activity. We have confirmed that the addition of this mutation (L167) did 
not affect the biological activity of p38 MAPK (fig. 5), we can observe that MKK6 is able 
to activate p38 MAPK with those mutations. Once this was confirmed, we wanted to 
confirm that the mutations introduced to p38 MAPK are able to accept ATP analogs. For 
this purpose we were using N6-Bn-ATP analog (this was based on previous studies that 
showed that this analog can be used for substrates identification). To screen the mutations 
of gatekeeper residue with the additional mutation to DFG motif within p38 to confirm 
they allow the use of the bulky ATP analog, we did a non-radioactive in vitro kinase 
assay, based on phosphorylation of known p38 MAPK substrate: ATF-2 (Fig. 6). 
It is necessary to find a compatible ATP analog, which will bind to the generated 
mutation, but will not bind to the wild type p3 8 MAPK. For this purpose we have tested 
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additional ATP analogs: N6-(2Methylbutyl)-ATP, and N6-cyclopenthyl-ATP (all the 
analogs were purchased from Biolog Life Sciences), as well as N6-Benzyl-ATP. Those 
three analogs were chosen based on previous studies that were done with engineered 
kinases and substrate identification. For the identification of Rous sarcomavirus tyrosine 
kinase substrates, that was done by Shah et al., N6-Cyclopenthyl-ATP analog showed to 
have best catalytic efficiency. For identification of CDKl and ERK2 N6-Bn-ATP was 
used, due its high catalytic efficiency (73,73). N6-2MeBu-ATP was also tested because it 
is a smaller analog. p38 ATP gatekeeper residue is relatively small amino acid (Thr), 
unlike other kinases that have bigger amino acid at the gatekeeper residue, like isoleucine 
in ERK.2, or methionine in JNK, that is why smaller analog might have better catalytic 
efficiency. N6-2MeBu-ATP is the smallest synthesized analog among all the three that 
were tested. Our results of in vitro kinase assay in comparison with ATP analogs or ATP 
have demonstrated that our generated mutations did not phosphorylate ATF-2 efficiently, 
from this can be concluded that the ATP analogs did not bind well with the generated 
ATP pocket (Fig. 8). We observed that ATP is able to phosphorylate ATF-2 with higher 
catalytic activity than ATP analogues. We have concluded from that, that the mutations 
that were introduced to p38 MAPK might not have enough space in the pocket to accept 
ATP analogues. 
To generate a p38 MAPK that might be more capable of utilizing ATP analogs, 
we introduced an additional mutation at L87, based on computational analysis of p38 
MAPK structure. The computational analysis indicated that L87 residue is part of the 
ATP binding pocket, and changing this residue to a smaller amino acid (alanine) might 
so 
increase the size of the ATP binding pocket (fig. 9). To screen these mutations of 
gatekeeper residue with the additional mutation L87 within p38 MAPK to confirm they 
allow the use of the bulky ATP analog, we did an in vitro kinase assay, based on 
phosphorylation of known p38 MAPK substrate, ATF-2. Our results of in vitro kinase 
assay have shown that there is phosphorylation of ATF-2 by activated p38 MAPK with 
the additional mutation L87 and the gatekeeper residue mutation. It seems that the L87 
mutation in combination with the gatekeeper residue mutation has resulted in structural 
changes to the ATP binding site. Specifically, figure 9 shows that L87A/T106G mutation 
is able to utilize ATP analogues and phosphorylate ATF-2. We have compared p38 
MAPK mutations in kinase assays with ATP or ATP analogues. The fact that ATP is able 
to phosphorylate p38 MAPK mutations should not be a concern, since previous published 
studies have shown that generated kinase mutation is able to use ATP analog and ATP in 
similar manner (82). This result is important because it shows that we were successfully 
able to generate p38 MAPK mutation that can be used for substrate identification in a 
whole cell lysate. It seems that we have identified a residue that can increase ATP binding 
pocket size and allow ATP analogues to bind more efficiently, without losing its catalytic 
activity. This new discovery can help with the identification of new substrates of p3 8a. 
Our results of in vitro kinase assay have shown that N6-2MeBu-ATP is the analog 
that can phosphorylate ATF-2, from this can be concluded that there is better binding to 
the generated p38 MAPK mutation ofL87A+T106G; it has the best catalytic efficiency. 
This was the analog that was used by p38 MAPK mutation, but was not used by wild type 
51 
p38 MAPK. The other analogs were also been able to phosphorylate the generated 
mutations, but they were also used by the wild type p38 MAPK (fig. 10). 
From all the six generated mutations, the one that worked the best was T106G+L87A. 
Those two mutations have generated an ATP binding pocket that can accept synthesized 
ATP analog, but cannot be used by wild type p38 MAPK. Based on our results, 
Tl06A+L87A can also accept ATP analogs to phosphorylate a known substrate, but not 
as efficiently as the mutation to the gatekeeper residue when Tl 06 is exchanged to Gly. 
Our results also showed, based on in vitro kinase assay, that the additional mutation to the 
DFG motif(L167) that is supposed to enhance ATP binding site activity did not do that; it 
was not phosphorylating ATF-2 efficiently, which implies that this double mutation did 
not accept ATP analog (fig. 6). Surprisingly, all the three mutations (T106+ L167+L87) 
were not able to accept the ATP analog and phosphorylate ATF-2 either (fig. 10). This 
maybe because the structural changes lead to chemical changes, that will interfere with 
the ATP binding. Another reason might be because the L 167 residue is located farther 
from the ATP site (fig 9A), hence it doesn't have much effect on the ATP binding pocket. 
From this, was concluded that T 106G+ L87 A is the mutation that can accept ATP analog, 
without losing its biological function. This p38 MAPK mutation can be used further for 
substrate identification. 
We have radioactively labelled N6-2MeBu-ADP with yP32. The enzymatic 
labelling of N6-2MeBu-ADP with yP32was done with NDPK. Radioactive labelling 
allows us to track the direct substrates of the kinase in question. Our result of radio labeled 
yP32 N6-2MeBu-ATP was not successful. Based on our results of in vitro kinase assay, 
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yP32 N6-2MeBu-ATP did not phosphorylate ATF-2 (data not shown). There is a 
possibility that NDPK was not catalytically active. If NDPK is not catalytically active, it 
is unable to transfer phosphor from yP32ATP to analog ADP, what will result that we are 
unable to visualize p38 MAPK substrates on autoradiography. This is a possibility due to 
the fact that we have tested and seen that the analog and the mutations of p3 8 MAPK that 
were generated are working in a "cold" assay, and able to phosphorylate ATF-2. 
Labelling approach is good for visualising substrate phosphorylation, but it is hard to 
identify the phosphorylated proteins. The way to identify proteins is mass spectrometry. 
The next step to do for substrate identification will be mass spectrometry. Mass 
spectrometry analysis is a very common technique for protein analysis and identification. 
This proteomics technique has a potential in identifying new signalling targets to give 
insight into the mechanism of cellular control (83). In this technique, the proteins in the 
complex are separated on SDS-PAGE gel and then stained either by coomassie or silver 
staining, the radiolabeled silver-stained band are excised. The excised proteins then go 
through proteolysis (usually with trypsin). Mass spectrometry is followed to analyse the 
peptides, by peptide separation on 2D-gel electrophoresis (83). Phosphorylation of 
cellular homogenate by yP32(analog) ATP will lead to a mixture of highly phosphorylated 
proteins. The y-thiol-phosphate of ATP serves as the kinase transferable tag, which 
allowsto purify proteins from tryptic digestion (73 ). This method relies on the unique 
ability of the mutated kinase to utilize and use the ATP analog, any nonspecific utilization 
of the ATP analog by other kinases in the cell will increase the false-positive substrate 
identification (79). To identify direct substrates of the mutated kinase, thiophosphorylated 
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substrate peptides captured on a solid-phase agarose, then released by oxidative 
hydrolysis, this will yield phosphorylated peptides (73). The newly phosphorylated 
proteins are isolated and identified by mass spectrometry. The next step of analysis is 
database searching and statistical use of software to interpret mass spectrometry data, 
which will give a list of proteins that were present in the initial sample (84, also reviewed 
by 85). The aquired data from mass spectrometry is analysed by Mascot sequence 
alignment algorithm (73).From this list of proteins, we can identify substrates that are 
already known and also those that are not yet known. Those substrates that are not known 
will need further molecular analysis to understand their role in the cell and the molecular 
mechanism. Once substrates identified, there is further investigation need to done to 
understand their role in the pathway of p38 MAPK and their characterization. As well, it 
is important to establish whether these "new" substrates are physiological substrates of 
p38MAPK. 
In conclusion, in our current study, despite the fact that we were not able to 
identify new substrates, we have identified a residue (L87) in ATP binding pocket, which 
will allow binding of synthesized ATP analogs. L87 residue is a conserved residue 
evolutionarily (Fig. 11). We have followed the four criteria that need to be met to 
engineer a kinase successfully; we have mutated p38 MAPK that is expressed in the cell 
context, we have engineered the p38 MAPK ATP binding site to accept ATP analogs, p38 
MAPK was able to phosphorylate a known substrate ATF-2 with ATP analogs, and 
finally wild type p38 MAPK does not accept ATP analog: N6-2MeBu-ATP. We have 
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successfully mutated p38 MAPK to accept synthesized ATP analog. This generated 
mutation of p38 MAPK can be further used for substrate identification. 
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Appendix: 
Molecular Techniques 
Cell Culture: 
Reagents: 
IX Dulbecco's PBS (IL, pH 7.4: NaCl 8gr, KCL 0.2 gr Na2HP04 7H20 I .44 gr, KH2P04 
0.24 gr) 
Versine (0.2 gr EDTA in IL lX PBS) 
Trypsin (0.125 Trypsin EDTA (Gibco) diluted in Versine) 
Growth Medium (GM): DMEM supplemted with I% Penicillin-streptomycin and I% L-
Glutamine and 10% Fetal Serum Albumin (FBS) 
Freezing Medium: Growth medium supplemented with 10% DMSO 
Methods: 
Thawing cells: 
1. Remove the vial of frozen cells from -80°C and thaw in 37°C water bath 
2. Mix Iml of the cells with 5ml of growth medium in 15ml falcon tube 
3. Centrifuge for 5min at 1500 rpm to pellet the cells 
4. Aspirate the supernatant from the falcon tube 
5. Add IO ml growth medium to the cells, pipette up and down for proper mixing 
and plate the cells in I Ocm plate 
Passing cells: 
I. Aspirate the media from I Ocm plate 
2. Wash cells in IX PBS 
l 
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3. Add lml 0.125 % Trypsin incubate for 1 min in 37°C 
4. Flick the plate to detach the cells 
5. Add cells to a new culture plate in a ratio of 1 :6 containing growth medium 
6. Incubate cells at 37°C and 5% C02 overnight 
Freezing cells: 
1. Follow steps 1-4 for passing cells 
2. Pellet the cells in a falcon tube in 5ml growth medium with centrifugation at 1500 
rpm for 5 min 
3. Aspirate the media and add freezing media to the falcon tube, pipette up and down 
for better suspension 
4. Aliquot 1 ml of cell in freezing vials 
5. Store the cells in -80°C until further use 
Transient transfection of mammalian cells with DNA: 
Reagents: 
2X HEBS (pH 7.15: 280mM NaCl, 1.5 mM Na2HP04, 50 mM Hepes) 
Filter, sterilize and store in -20°C 
2.5 M CaCh (36.75gr CaCh in lOOnil ddH20), filter, sterilize and store in -20°C 
Method: 
1. Seed cells 24 hours prior to transfection at 60-70% confluency 
2. Re- feed cells with growth medium three hours before transfection 
3. Add 0.5ml 2X Hepes into sterile culture tubes 
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4. To prepare DNA- CaCh mixture, add ddH20 to 25µg DNA to reach 450 µl, and 
add 50µ1 CaCh, mix gently 
5. Add DNA- CaCh drop wise into 2X Hepes tube on the vortex with low speed 
6. Add the final mixture to the cell culture drop wise 
7. After 16-18 hours wash cells twice with lX PBS and add growth medium 
8. Check dsRED signal after 24 hours and then harvest cells 
Harvesting cells: 
Reagents: 
lX Dulbecco's PBS (lL, pH 7.4: NaCl 8gr, KCL 0.2 gr, Na2HP04 7H20 1.44 gr, KH2P04 
0.24 gr) 
lx Cell lysis buffer (20mM Tris pH 7.5, 150mM NaCl, lmM EDTA, lMm EGTA, 
1 % Triton, 2.5 mM sodium pyrophosphate, lmM ~- glycerophosphate, lmM Na3 V04, 
1 µg/ml Leupeptin) 
Method: 
1. Remove media and add cold lx PBS. Wash twice with lxPBS 
2. Remove PBS and add 0.5ml lx Cell Lysis buffer plus lmM phenylmethylsulfonyl 
(PMSF) and lmM Na3Vo4 to each lOcm plate, and incubate on'ice for 5 min 
3. Scrape cells off the plate and transfer to eppendorf tube 
4. Sonicate lysates on ice 4 times for 5 seconds each 
5. Microcentrifuge for 10 min at 4 ° C at 16000xG, and transfer the supernatant to a 
new tube. Store in -80°C 
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Immunoprecipitation and in vitro kinase assay: 
Reagents: 
Anti HA affinity matrix 
lx Cell lysis buffer (20mM Tris pH 7.5, 150mM NaCl, lmM EDTA, lMm EGTA, 
1%Triton, 2.5 mM sodium pyrophosphate, lmM ~- glycerophosphate, lmMNa3V04, 
I ug/ml Leupeptin) 
lx Kinase buffer (25mM Tris pH 7.5, 5Mm ~- glycerophosphate, 2mM DTT, 0.1 mM 
Na3V04, lOmM MgCh) 
ATF-2 Fusion protein 
10 mM ATP/ lOmM ATP analog 
Methods: 
1. Add 20µ1 of Anti Affinity HA beads to 200µ1 of cell lysate 
2. Incubate overnight with gentle rocking at 4°C 
3. Microcentrifuge cell lysate at 16,000xG for 1 min at 4°C 
4. Wash pellet twice with 0.5 ml lx Cell lysis buffer 
5. Aspirate buff er from the tube and microcentrifuge at 16000xG for 1 min at 4 ° C 
6. Wash pellet twice with 0.5 inl lx Kinase buffer 
7. Aspirate buffer from the tube and microcentrifuge at 16000xG for 1 min at 4 ° C 
8. Re-suspend pellet in 40µ1 lx Kinase buffer, and add it to the kinase reaction 
250µM ATP/ATP analog and lmg of ATF-2 fusion protein 
9. Incubate for 30 min at 30°C 
10. Terminate reaction by adding 13.3µ14x SDS Sample Buffer and vortex 
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Western Blotting: 
Reagents: 
1.5M Tris-HCL, pH 8.8 
lM Tris-HCL, pH6.8 
10% Ammonium Persulphate (APS) 
Terned 
TBST (lOX TBS: 80gr NaCl, 24.2 gr Tris, pH 7.6) - lX TBS+ 0.5% Tween-20 
Transfer Buffer (For lL: 3gr Tris, 14.4 gr Glycine, 20% Methanol) 
Methods: 
1. Prepare resolving and stocking solutions, cast the gel according to western 
blotting techniques. 
2. Load 15µ1 per well and load 5µ1 marker on 10% SDS-PAGE gel 
3. Run the gel at 1 OOV for approximately 1.5 hours 
4. Transfer the proteins to Immobilin-FL membranes (Millipore) for 1 hour at lOOV 
5. After transfer wash the membranes with PBS or THST buffer at room temperature 
6. Block membranes for 1 hour at room temperature in 5%milk in PBS or TBST 
buffer with gentle rocking 
7. Dilute primary antibodies in the appropriate buffer and incubate over-night at 4°C 
8. Wash membranes 3 times for 5 min in PBS or TBST 
9. Incubate membrane with secondary antibody (1 :3000) for 2 hours with gentle 
rocking at room temperature 
10. Wash membranes 3 times for 10 min in PBS or TBST 
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11. Add Enhanced Chemiluminescence (ECL) to each membrane, expose to a film to 
detect proteins 
6XHN- NDPK protein purification: 
Reagents: 
Terrific Broth (for lL: in 900 ml of ddH20 -tryptone 12gr, yeast extract 24 gr, glycerol 
4ml. Add I 00 ml of sterile solutions of O. I 7M KH2P04, 0.72M K2HP04) 
Carbencillian I OOµg/ml 
lmM IPTG (2.383 gr in 10 ml ddH20) 
IM Imidazole (34.04 gr on 0.5L ddH20) 
Binding buffer (50 mM Tris pH 7.5, 500Mm NaCl, 5mM Imidazole and I:IOO protease 
inhibitors) 
Wash Buffer (50 mM Tris pH 7.5, 500mM NaCl, 30mM Imidazole) 
Elution Buffer (50mM Tris pH 7.5, 500mM NaCl, 250mM.Imidazole) 
HKG buffer (20mM Hepes pH 7.4, 250mM KCL, 20% (v/v) glycerol) 
Ni-Nta agarose beads (purchased from Qiagen, cat.# 30210) 
Methods: 
1. 6x HN -NDPK was grown overnight with shaking at 37°C in 100 ml Terrific.broth 
(TB) culture with lOOµg/ml carbencillian 
2. IOOml of TB was added to IL of fresh TB culture. When the OD600 reading 
reaches 1, the culture is stimulated with lmM IPTG 
3. The culture was incubated overnight at I6°C with shaking 
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4. Cells were pelleted by centrifugation at 5000rpm for 10 min and resuspended in 
60 ml of binding buffer 
5. Cells were lysed by sonication at 30% amplitude, 2sec on 3sec off, for a total of 6 
mm. 
6. Insolubles were pelleted by centrifugation at 1800rpm for 30 min at 4°C, and the 
supernatant was bound to 5ml Ni-Nta beads at 4°C for 20 min with gentle rocking 
7. The binding supernatant was flown through the column 2-3 times 
8. Ni-Nta beads were washed with 1 Ox column volumes with wash buffer 
9. 6XHN-NDPK was then eluted from the column in 5ml fractions with elution 
buffer 
10. Samples with the eluted fraction were separated by 15% SDS-PAGE and 
coomasie stained to assess protein levels and purity 
11. The fractions with the highest NDPK levels were dialyzed against three changes 
of HKG buffer. Fractions were stored at -80°C 
ATP analog labelling: 
Reagents: 
Ni-Nta agarose beads 
lX Dulbecco's PBS (lL, pH 7.4: NaCl 8gr, KCL 0.2 gr, Na2HP04 7H20 1.44 gr, KH2P04 
0.24 gr) 
Hepes buffered saline (HBS): (150mM NaCl, lOOmM Hepes pH 7.4) 
lmci ofyP32 ATP purchased from Perkin Elmer (6000Ci/mmole 150mCi/ml) 
1 OmM ADP analog purchased from Bio Log Life Sciences 
I. 
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5mM MgCh (50.825gr in 0.25L ddH20) 
Gamma P32-ATP (purchased from Perkin Elmer, cat.# NEG035C001MC) 
Methods: 
The following was adapted from Current Protocols in Molecular Biology 18.11.8. 
1. To a Bio- disposable column, add 200µ1 of 1: 1 slurry Ni-Nta beads 
2. Add lml ofHBS and allow the buffer to drain until level with the top of the beads 
3. Add 165µg purified 6xHN-NDPK. Bind NDPK to the beads for 20 min by gentle 
rocking at 4 ° C 
4. Wash the column with lX PBS buffer 
5. lµci ofyP32 with 200µM cold ATP (as a carrier) was added to the reaction diluted 
in lx PBS 
6. Wash 5 times with lX PBS 
7. 80nmole ofN6-ADP analog was added to the column and diluted in lX PBS+ 
5mMMgCh 
8. Elute with 250µ1 of lxPBS containing 5mM MgCh. Store aliquots in -80°C 
Mutagenesis: 
Reagents: 
Primers ordered from Sigma Aldrich 
PFU ultra DNA polymerase enzyme (Agilent, cat. # 600380) 
lOmM dNTP's purchase Cell Signaling Techologies 
1 Ox Buffer purchased from Stratagine 
Mineral Oil 
i_ 
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l' --~-,-
1 
DpnI purchased from New England BioLabs, cat.# R0176S 
Methods: 
The set-up of the reaction was done based on Quickchange II Site directed mutagenesis 
kit (Stratagene) 
1. Prepare mixture of primers, DNA template, 1 Ox buffer, dNTP' s, ddH20 and PFU 
ultra enzyme for a total volume of the reaction 50µ1 as per kit instructions 
2. Add 40µ1 of mineral oil to the top of the sample 
3. Amplify samples using PCR 
4. PCR-amplified samples were then aliquoted without the mineral oil. lµl ofDpnI 
was added 
5. Incubate at 3 TC for 1 hour 
6. DNA samples were then transformed in 50µ1 of BL21 E.Coli bacteria 
7. Incubate for 30 min on ice 
8. Heat shock samples for 1 min at 42°C, place the reaction on ice for 2 min to 
recover 
9. Add 200µ1 of LB +0.1 % glucose per sample, and incubate for 30 min at 37°C 
10. Spread 50µ1 on agar plate and grow plate overnight at 37°C 
Primers used for mutagenesis: 
Forward Tl06A: 5'- GATGTGTATCTGGTGGCCCATCTCATGGGGG- 3' 
Antisense Tl 06A: 5 '-CCCCCATGAGATGAGATGGGCCACCAGAT ACACATC-3' 
Forward Tl06G: 5'-ATGATGTGTATCTGGTGGGCCATCTCATGGGGGCAG-3' 
Antisense Tl 06G: 5 '-CTGCCCCCATGAGATGGCCCACCAGATACACATCAT-3' 
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Forward L167A: 
5 '-TGAAGACTGTGAGCTGGAAGATTGCGGATTTTGGACTGGCT-3' 
AntisenseL 167 A: 
5 '-AGCCAGTCCAAATCCGCAA TCTTCAGCTCACAGTCTTCA-3' 
Forward L87 A: 
5 '-CATGAAATGTGATTGGTCTGGCGGACGTTTTT ACACCTGCAA-3' 
Antisense L87 A: 
5' -CTTGCAAGGTGT AAAAACGTCCGCCAGACCAATCACATTTTCATG-3' 
p38 primers used: 
Forward 1: 5'- ATGTCTCAGGAGAGGCCCA-3' 
Forward 3: 5'- GGATTTTGGACTGGCTCG-3' 
Forward 5: 5'-TAGATGAGTGGAAAAAGCC-3' 
Supplementary data: 
Purification of NDPK: 
For the procedure of labelling ATP analogs, purification of nucleoside 
diphosphate kinase (NDPK) protein was needed. NDPK is an enzyme that catalyzes the 
exchange of phosphate groups, it will catalyze the phosphorylation reaction of 
ADP7 ATP. The enzyme phosphorylates itself on a conserved histidine residue at the 
catalytic site, and then it transfers the phosphate (80). ATP or GTP is used as a donor, 
while ADP or GDP is a good substrate for pyruvate kinase. The reaction is active as a 
complex with Mg +2• The nucleoside di phosphate binds to the free enzyme, while 
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nucleoside triphosphate binds to the phosphorylated enzyme. ATP is generated if NDPK 
is incubated with phosphoramidate and ADP (81 ). 
For the purpose of our study NDPK was used to label gamma P32 ADP analog and 
transform it into labelled ATP. Labelled ATP will transfer the gamma phosphor into the 
substrate once the substrate is phosphorylated by p38. 
NDPK was purified from bacteria through an N~-Nta column and was stained by 
commasie blue to assess protein levels and purity. Those fractions that had the highest 
NDPK levels were dialyzed. This was used for ATP labelling. 
NDPK was used to label ADP analog with VP32 to VP32 ATP analog, and that was used for "hot" 
in vitro kinase assay as the phosphate source for substrate phosphorylation with mutations of p38. 
NDPK was also identified by mass spectrometry after it was stained, to make sure we have the 
right protein product (this is due to the important purpose NDPK serves). 
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Figure14:6XHN-NDPK purification on Ni-Nta column. Fractions were eluted from the column. (A) All 
fractions werecollected and their OD was measured to asses that fractions were washed and the elution was 
with NDPK protein. (B) Eluate samples were separated by 15% SDS- page and commasie stained to 
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assesprotein levels and purity. Thosefractions that were the highest NDPK levels were dialyzed and used 
for ATP labeling. In our case fraction 2 had thehighest protein levels, and that was used for ATP labeling. 
1 MSSQTERTFI AVKPDGVQRG LVSQILSRFE KKGYKLVAI~ LVKADDKLLE 
51 QHYAEHVGKP FFPKMVSFMK SGPILATVWE Gl<DWRQGR~ ILGATNPLGS 
101 APGTIRGDFG IDLGRNVCHG SDSVDSAERE INLWFKKEEL VDWE1$NQAKW 
151 !YE 
Figure 15: Identification of NDPK. Tandem mass spectrometry of excised spot from figure 12, fraction 2 
was sent for identification since it showed to be the highest level of protein purity. The sequence above 
shows tha~ it was identified as Ynklp, which is Nucleoside diphosphate kinase of Saccharomyces 
cerevisiae. Matched peptides shown in bold red. 
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